clinical trial · NCT07764146
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Alzheimer s DiseaseVY1706 Low doseVY1706 Mid doseVY1706 High DoseAnti-AAV9 Total Antibody (TAb) Assay
brief summary
VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
started
Sep 3, 2026
primary completion
Apr 28, 2029
completion
Apr 28, 2029
last updated
Oct 29, 2026
official title
An Open Label Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of VY1706 in Participants With Early Alzheimer's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol